이 누리집은 대한민국 공식 전자정부 누리집입니다.
Biz News Korea(Eng)
- Collected
- 2019.08.16
- Distributed
- 2019.08.17
- Source
- Go Direct
[Herzuma]
Celltrion Healthcare, the marketing and distribution arm of South Korean biosimilar maker Celltrion, said on Friday that its breast cancer biosimilar Herzuma continued to gather ground in the first quarter of the year, taking up 13 percent share of the original trastzumab market in Europe.
According to the company, a recent report by healthcare consulting firm IQVIA showed that market share of Herzuma represented a 13 percent of the reference drug Herceptin market in the January-March period, increased from 10 percent three months earlier.
Herzuma was launched in seven European countries in the second quarter of last year and the market share was 6 percent in the third quarter of that year.
[Remsima and Truxima]
Herzuma is Celltrion’s third biosimilar launched in Europe. The two others are Truxima and Remsima, which also showed robust growth in the first quarter.
Truxima took a 37 percent share in the European market, up 1 percentage point from three months ago, and Remsima`s share remained unchanged at 57 percent.
Celltrion Healthcare recently said its revenue came to 505.3 billion won ($416.7 million) in the first six months on a consolidated basis, up 62 percent from a year ago. Operating profit reached 18.7 billion won with a net profit of 14.3 billion won. The company said its full-year profitability will continue to improve throughout the second half when Truxima and Herzuma are set to be launched in the U.S.
By Kim Byung-ho and Minu Kim
[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]